Renal Transplant Rejection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for renal transplant rejection. 30 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
30
Active US patents
70/100
Avg vulnerability
$1.6B
Annual revenue covered

Originators in Renal Transplant Rejection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Astellas Pharma 30 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating renal transplant rejection. Each bar = one year. Y-axis scaled to peak year (30 patents).

30
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Prograf
TACROLIMUS
 Astellas Pharma 30 70 $1.6B 2028-05-30

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
12083103 Prograf method of use 88 2028-05-30
11110081 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30
10864199 Prograf method of use 75 2028-05-30
11123331 Prograf method of use 75 2028-05-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9549918 Prograf formulation 55 2028-05-30
10166190 Prograf formulation 55 2028-05-30
10166190 Prograf formulation 55 2028-05-30
9549918 Prograf formulation 55 2028-05-30
10166190 Prograf formulation 55 2028-05-30
9549918 Prograf formulation 55 2028-05-30
11419823 Prograf formulation 63 2028-05-30
11419823 Prograf formulation 63 2028-05-30
11419823 Prograf formulation 63 2028-05-30
12403095 Prograf formulation 68 2028-05-30

Related